Form 4: Apogee Therapeutics Insider Sells Shares

Michael Henderson, CEO of Apogee Therapeutics, sold 20,000 shares of common stock for $133.63 per share under a Rule 10b5-1 trading plan, and also gifted 75,046 shares to a donor-advised fund.

Summary

• Michael Henderson, Chief Executive Officer and Director of Apogee Therapeutics, Inc., reported transactions involving the company's common stock.
• On July 8, 2026, Henderson sold 20,000 shares of common stock at a weighted average price of $133.63 per share. This sale was executed as part of a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025.
• The sale involved multiple transactions with prices ranging from $133.52 to $133.70.
• Following this sale, Henderson beneficially owns 995,987 shares directly.
• On July 10, 2026, Henderson made a bona fide gift of 75,046 shares of common stock to a donor-advised fund.
• After the gift, Henderson directly beneficially owns 920,941 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the execution under a Rule 10b5-1 plan and the philanthropic gift mitigate strong negative sentiment.

Positives

• The sale of 20,000 shares was conducted under a Rule 10b5-1 trading plan, indicating pre-planned and potentially non-insider-trading-related activity.
• The gift of 75,046 shares to a donor-advised fund suggests philanthropic activity by the executive.

Negatives

• A significant number of shares (20,000) were sold by a key executive, which could be perceived negatively by the market.
• The sale occurred at a price of $133.63 per share, indicating a disposition of equity at a substantial valuation.

Risks

• The sale of shares by a CEO, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence in future stock performance.
• The specific details of the Rule 10b5-1 plan, including its adoption date and the range of sale prices, are important for assessing the context of the transaction.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is a common event for executives in the biotechnology sector, particularly when stock prices reach significant levels. The gifting of shares also aligns with typical philanthropic practices of high-net-worth individuals in the industry.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by the CEO as a potential signal, though the Rule 10b5-1 plan provides some context. The gift has no direct financial impact on shareholders.
• Employees: May also view the CEO's stock sale with concern, depending on their perception of the company's future prospects.
• Donors: Beneficiaries of the donor-advised fund will eventually benefit from the gifted shares.

Next Steps

• The reporting person will provide detailed transaction information upon request from the Issuer, security holders, or the SEC staff.

Key Dates

Keywords

Apogee Therapeutics, APGE, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Beneficial Ownership, Michael Henderson, CEO, Gift, Donor Advised Fund